Login to Your Account



TEETH INTO NASH NEXT?

Still ‘galectin’ CKD data, La Jolla considers oral form; shares roar

By Randy Osborne
Staff Writer

Tuesday, March 11, 2014
The higher-dose glitch in otherwise strong phase II results with its galectin-3-targeting chronic kidney disease (CKD) therapy did little to hold back shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC), which closed Tuesday at $17.96, up $7.06, or 64.8 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription